SMAD4 antibody

Synonyms:DPC4 antibody, MADH4 antibody
Catalogue No.:FNab07996Reactivity:Human, Mouse
Host:RabbitTested Application:ELISA, WB, IHC, IF
Clonality:polyclonalIsotype:IgG
  • SPECIFICATIONS
Product Name
SMAD4 antibody
Catalogue No.
FNab07996
Size
100μg
Form
liquid
Purification
Immunogen affinity purified
Purity
≥95% as determined by SDS-PAGE
Clonality
polyclonal
Isotype
IgG
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
Immunogen
SMAD family member 4
Alternative Names
DPC4 antibody, MADH4 antibody
UniProt ID
Q13485
Observed MW
60 kDa
Application
Tested Applications
ELISA, WB, IHC, IF
Recommended dilution
WB: 1:500-1:2000; IHC: 1:20-1:200; IF: 1:20-1:200
Validated Images
HEK-293 cells were subjected to SDS PAGE followed by western blot with FNab07996(SMAD4 antibody) at dilution of 1:600
Immunohistochemical of paraffin-embedded human breast cancer using FNab07996(SMAD4 antibody) at dilution of 1:100
Background
In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein(BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements(SBEs)(5'-GTCT/AGAC-3') within BMP response element(BMPRE) of cardiac activating regions(By similarity). Common SMAD(co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta(transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for synergistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.